Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Compugen Ltd (NQ: CGEN )

0.9300 -0.0333 (-3.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Compugen Ltd

< Previous 1 2 3 4 5 Next >
5 Analysts Have This to Say About Compugen
Via Benzinga
Compugen Earnings Preview
Via Benzinga
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
Via AB Newswire
Expert Ratings for Compugen
Via Benzinga
Compugen: Q1 Earnings Insights
Via Benzinga
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Earnings Preview: Compugen
Via Benzinga
Why Shares of Compugen Rose on Thursday
The clinical-stage biotech retreated a bit from one of its biggest days in a while. 
Via The Motley Fool
Why Shares of Compugen Rose 16.5% on Wednesday
Market factors and a company announcement helped the stock climb. 
Via The Motley Fool
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday. 
Via The Motley Fool
Why Compugen Stock Got Slammed Today
Clinical-stage biotechs are particularly susceptible to shifts in analyst sentiment. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
Via Benzinga
Why Compugen Stock Crumbled Today
Investors indicated their displeasure with the company's recent fundamentals. 
Via The Motley Fool
Why Shares of Compugen Jumped 9.27% on Tuesday
The stock's rise came after the company announced when third-quarter earnings will be presented. 
Via The Motley Fool
Analyst Ratings for Compugen
Within the last quarter, Compugen (NASDAQ:CGEN) has observed the following analyst ratings: 
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Compugen: Q2 Earnings Insights
  Compugen (NASDAQ:CGEN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
Why Shares of Compugen Jumped 17.86% on Thursday
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies. 
Via The Motley Fool
Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday
Gainers Pintec Technology Holdings Limited (NASDAQ: PT) shares jumped 216.2% to close at $0.9058 on Wednesday. 
Via Benzinga
5 Top Stocks Cathie Wood Sold This Week
August was not a pleasant month for Cathie Wood and ARKK as the ETF experienced outflows of $803 million, the most since last September. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 127 companies set new 52-week lows. 
Via Benzinga
Truist Securities Maintains Buy Rating for Compugen: Here's What You Need To Know
Truist Securities has decided to maintain its Buy rating of Compugen (NASDAQ:CGEN) and lower its price target from $14.00 to $4.00. Shares of Compugen are trading up 2.29% over the last 24 hours, at... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds... 
Via Benzinga
JMP Securities Maintains Market Outperform Rating for Compugen: Here's What You Need To Know
  JMP Securities has decided to maintain its Market Outperform rating of Compugen (NASDAQ:CGEN) and lower its price target from $8.00 to $4.00. Shares of Compugen are trading up 1.37% over the last 24... 
Via Benzinga
This Analyst Lowers Price Target On Lyft; Also Check Out Some Other Major PT Changes
Wells Fargo cut the price target on Lyft, Inc. (NASDAQ: LYFT) from $49 to $42. However, Wells Fargo analyst Brian Fitzgerald maintained the stock with an Overweight. Lyft shares rose 0.6% to $20.41 in... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.